ライフサイエンスコーパス: unstable angina

1 nts (composite of CAD death, nonfatal MI, or unstable angina).

2 y revascularization, and hospitalization for unstable angina).

3 or other acute coronary syndromes (including unstable angina).

4 -segment elevation myocardial infarction; 6% unstable angina).

5 .52; 95% CI, 0.31-0.88) were associated with unstable angina.

6 ry revascularization, or hospitalization for unstable angina.

7 ion, nonfatal stroke, or hospitalization for unstable angina.

8 the primary outcome plus hospitalization for unstable angina.

9 l infarction, stroke, or hospitalization for unstable angina.

10 classified as myocardial infarction (MI) and unstable angina.

11 rwent PCI for acute myocardial infarction or unstable angina.

12 he trial of death, myocardial infarction, or unstable angina.

13 t (within 3 months) myocardial infarction or unstable angina.

14 vation myocardial infarction, and 23.6% with unstable angina.

15 rehospitalization for progressive angina or unstable angina.

16 -STEMI (NSTEMI), and 19 777 (40% women) with unstable angina.

17 non-ST-elevation myocardial infarction, and unstable angina.

18 ion, ischemic stroke, or hospitalization for unstable angina.

19 cardial infarction and rehospitalization for unstable angina.

20 ndromes, including myocardial infarction and unstable angina.

21 her vascular events, and hospitalization for unstable angina.

22 8 months after receiving 2 Cypher stents for unstable angina.

23 for death, acute MI, or hospitalization for unstable angina.

24 fatal stroke, coronary revascularization, or unstable angina.

25 ups and do not include subgroup analysis for unstable angina.

26 events, including 141 MIs and 84 episodes of unstable angina.

27 ns exist regarding the use of angiography in unstable angina.

28 hemic stroke, transient ischemic attack, and unstable angina.

29 iagnosis in 1 man was downgraded from AMI to unstable angina.

30 , and stroke, as well as hospitalization for unstable angina.

31 non-fatal stroke) or hospital admission for unstable angina.

32 coronary syndrome (myocardial infarction or unstable angina) 1-12 months before randomisation and wh

33 reatments for acute myocardial infarction or unstable angina (10%), treatments for heart failure (9%)

34 rdial infarction, 105,708 [21.1%]; high-risk unstable angina, 146,464 [29.3%]), and 144,737 (28.9%) f

35 ial infarction, 13.1% (95% CI, 1.1-23.7) for unstable angina, 16.4% (95% CI, 15.1-17.7) for heart fai

36 non-ST-elevation myocardial infarction, 218 unstable angina, 163 sudden cardiac death); 188 (9%) per

37 her in the MI group (7.5%) compared with the unstable angina (2.7%) and non-ACS (2.6%) groups (P < .0

38 mized 360 patients presenting with stable or unstable angina (28% of patients) and negative Troponin

39 I) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%).

40 and RITA-3 (Randomized Intervention Trial of Unstable Angina 3) non-ST-elevation acute coronary syndr

41 al infarction, 83.8% [95% CI, 83.3-84.4] for unstable angina, 30.5% [95% CI, 29.3-31.6] for heart fai

42 in both groups were males who presented with unstable angina; 36% were diabetic.

43 Stable and unstable angina accounted for most (43%) of the cardiova

44 infarction, coronary revascularisation, and unstable angina (active treatment HR 0.89, 95% CI 0.79-0

45 mic stroke, myocardial infarction, new-onset unstable angina, acute coronary interventions, and vascu

46 urgent CS patients (left main stenosis with unstable angina, acute endocarditis, valvular regurgitat

47 acute coronary syndromes (ACS) present with unstable angina, acute myocardial infarction, and sudden

48 e for coronary thrombosis, the main cause of unstable angina, acute myocardial infarction, and sudden

49 group 5) were more likely to be admitted for unstable angina (adjusted OR, 1.46 [95% CI, 1.04-2.05]).

50 over the initial year of treatment and more unstable angina admissions (hazard ratio=2.8 [1.1-7.5]).

51 evascularisation alone (0.84, 0.75-0.94) and unstable angina alone (0.81, 0.67-0.97) during full foll

52 placebo, on acute coronary syndromes (MI and unstable angina) among IRIS participants.

53 Patients with unstable angina and electrocardiographic changes or non-

54 Trial participants had typical symptoms of unstable angina and frequently had a positive electrocar

55 Likewise, clinical scenarios with unstable angina and intermediate- or high-risk features

56 ased risk of acute ischemic coronary events (unstable angina and myocardial infarction) equal to 4.5%

57 2220 patients hospitalized with unstable angina and non-ST-segment elevation MI who were

58 e ischemic outcomes in elderly patients with unstable angina and non-ST-segment elevation MI.

59 ctrum of clinical presentations ranging from unstable angina and non-ST-segment elevation myocardial

60 initiative included high-risk patients with unstable angina and non-ST-segment elevation myocardial

61 ed risk of adverse outcomes in patients with unstable angina and non-ST-segment elevation myocardial

62 t elevation acute coronary syndromes include unstable angina and non-ST-segment elevation myocardial

63 s significant reduction in revascularization/unstable angina and nonsignificant reductions in other c

64 during the study, both in the placebo group (unstable angina and pneumonia).

65 ath and myocardial infarction) or secondary (unstable angina and revascularization) events.

66 T-segment-elevation myocardial infarction or unstable angina) and stable presentation (51% stable ang

67 ry revascularization, or hospitalization for unstable angina) and total key secondary composite endpo

68 yocardial infarction, or hospitalization for unstable angina), and healthcare expenditures.

69 ry artery disease, 2806 hospitalizations for unstable angina, and 1029 fatal or nonfatal strokes occu

70 Fifty-nine percent presented with new unstable angina, and 9.3% presented with nonfatal myocar

71 arbepoetin, with higher incidences of death, unstable angina, and arrhythmia with peginesatide.

72 MACE endpoint also included all-cause death, unstable angina, and coronary revascularization.

73 cularization procedures, hospitalization for unstable angina, and diagnosis of new ischemic heart dis

74 dial infarction (MI), heart failure, stroke, unstable angina, and freedom from angina.

75 hypertension, diabetes, renal insufficiency, unstable angina, and heart failure, but less smoking.

76 atal stroke, urgent revascularisation due to unstable angina, and hospital admission for heart failur

77 on, non-fatal stroke, hospital admission for unstable angina, and hospital admission for heart failur

78 chemic attack, intracerebral hemorrhage, and unstable angina, and inverse (0.69) for subarachnoid hem

79 resenting clinical syndromes (stable angina, unstable angina, and MI).

80 dial infarction, coronary revascularisation, unstable angina, and new angina during active treatment

81 -ST-segment-elevation myocardial infarction, unstable angina, and non-acute coronary syndrome) in The

82 cardial infarction, acute coronary syndrome, unstable angina, and stroke) is unclear.

83 ther events, including recurrent infarction, unstable angina, and stroke.

84 le, diabetic, not currently smoking, to have unstable angina, and to have a prior PCI.

85 -segment elevation myocardial infarction and unstable angina, and venous thromboembolism prophylaxis.

86 xamined: (1) myocardial infarction (MI); (2) unstable angina; and (3) revascularization not associate

87 stive failure, hypertension, prior CABG, and unstable angina; and had higher body mass index and lowe

88 cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke).

89 rction [MI], congestive heart failure [CHF], unstable angina, arrhythmia, symptomatic hypotension, or

90 nfarction, stroke, admission to hospital for unstable angina, arterial revascularisation, or cardiova

91 al infarction or stroke, hospitalisation for unstable angina, arterial revascularisation, or cardiova

92 infarction, non-fatal stroke, admission for unstable angina, arterial revascularisation, or cardiova

93 al infarction or stroke, hospitalization for unstable angina, arterial revascularization, or cardiova

94 ardial infarction, stroke, hospital stay for unstable angina, arterial revascularization, or confirme

95 scular disease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or

96 s with recent acute myocardial infarction or unstable angina as a prognostic indicator for eventual c

97 idual manifestations (myocardial infarction, unstable angina) as secondary outcomes.

98 atal ischemic stroke, or hospitalization for unstable angina-as well as total nonfatal cardiovascular

99 Patients with unstable angina benefit from an invasive management path

100 dial infarction (MI), or hospitalization for unstable angina by 1 year.

101 on Therapy) were used to report rates of MI, unstable angina, cardiac arrest, and cardiac death and t

102 Annual rates of a composite of MI, unstable angina, cardiac arrest, and cardiac death were

103 ained ACS, defined as myocardial infarction, unstable angina, cardiac arrest, or death due to ischemi

104 MACE defined as acute myocardial infarction, unstable angina, cardiogenic shock, ventricular arrhythm

105 lization for nonfatal myocardial infarction, unstable angina, congestive heart failure, emergency cor

106 dial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart fa

107 ents including death, myocardial infarction, unstable angina, coronary revascularization, stroke, tra

108 (fatal and nonfatal myocardial infarctions, unstable angina, deaths from coronary heart disease, fat

109 ercutaneous coronary intervention [PCI], and unstable angina) derived from previous studies.

110 Patients with a stable or unstable angina diagnosis or documented silent ischemia

111 o be male, younger, and with higher rates of unstable angina, emergency operation, recent or transmur

112 king, prior revascularization, hypertension, unstable angina, female sex, nonwhite race, and US locat

113 The adjusted odds of MACE for the unstable angina group were similar to those for the non-

114 s severe types of ACS at presentation (e.g., unstable angina > non-ST-segment elevation MI > ST-segme

115 002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.7

116 Reductions in risk of hospitalization for unstable angina (hazard ratio, 0.55; 95% confidence inte

117 cted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-

118 non-fatal stroke, admission to hospital for unstable angina, heart failure, and all-cause mortality.

119 , myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular

120 yocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac

121 yocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac

122 condary analysis, additional events included unstable angina, heart failure, or stroke at five years.

123 cular disease events (myocardial infarction, unstable angina, heart failure, or stroke) in relation t

124 or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, d

125 or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, o

126 s all-cause death, myocardial infarction, or unstable angina hospitalization over a median follow-up

127 rtality, nonfatal myocardial infarction, and unstable angina hospitalization was similar and fair for

128 omposite of death, myocardial infarction, or unstable angina hospitalization.

129 d point was death, myocardial infarction, or unstable angina hospitalizations over a median follow-up

130 d toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P = 0.0

131 ndication was MI in 32.8% of the procedures, unstable angina in 33.8%, and non-ACS in 33.4%.

132 nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hyperte

133 all patients treated with PCI for stable or unstable angina in small native coronary vessels (refere

134 ss the effect of angiography on mortality in unstable angina, incorporating the results of additional

135 tion, stroke, coronary revascularisation, or unstable angina; key secondary endpoint was the composit

136 all-cause mortality, myocardial infarction, unstable angina leading to hospitalization, and revascul

137 female gender, body mass index <25 kg/m(2), unstable angina, moderate or poor ejection fraction, and

138 I (adjusted OR, 0.77; 95% CI, 0.63-0.95) and unstable angina, mortality was lower among women (adjust

139 We examined the risk of unstable angina, myocardial infarction, coronary revascu

140 evels), major adverse cardiovascular events (unstable angina, myocardial infarction, death), and safe

141 /=65 years of age who were hospitalized with unstable angina, myocardial infarction, heart failure, i

142 Emergently admitted patients with unstable angina (n = 33 901) who did or did not receive

143 due to myocardial infarction (n = 4; 13.8%), unstable angina (n = 8; 27.6%), congestive heart failure

144 sion [n = 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmi

145 gible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial inf

146 disease symptoms (congestive heart failure, unstable angina, non-ST-elevation myocardial infarction,

147 ndrome encompasses three clinical diagnoses: unstable angina, non-ST-segment elevation myocardial inf

148 clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infa

149 asymptomatic/mild angina, stable angina, and unstable angina/non-ST-elevation myocardial infarction b

150 Diagnosing unstable angina/non-ST-segment elevation myocardial infa

151 al presentation, diagnosis, and treatment of unstable angina/non-ST-segment elevation myocardial infa

152 ce of these agents in treating patients with unstable angina/non-ST-segment elevation myocardial infa

153 s and DAPT in the postdischarge treatment of unstable angina/non-ST-segment-elevation myocardial infa

154 s among specific PPI agents in patients with unstable angina/non-ST-segment-elevation myocardial infa

155 yocardial infarction [STEMI] and 15,459 with unstable angina/non-STEMI [UA/NSTEMI]), of whom 10 613 (

156 ry revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who

157 ation for chest pain, hospital admission for unstable angina or acute myocardial infarction [AMI], 30

158 blind randomised trial in 1439 patients with unstable angina or acute myocardial infarction.

159 ypertension and 28 cardiovascular events (17 unstable angina or arrhythmia, 3 nonfatal stroke, 3 hear

160 ypertension and 31 cardiovascular events (11 unstable angina or arrhythmia, 8 nonfatal myocardial inf

161 rdiac death, myocardial infarction (MI), and unstable angina or congestive heart failure warranting h

162 Eligible patients had stable or unstable angina or documented silent ischaemia, and a ma

163 reference group and had the highest risk of unstable angina or myocardial infarction (HR, 5.84 [3.43

164 (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an

165 sified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segm

166 Among patients with unstable angina or myocardial infarction without ST-segm

167 n=375,886) or acute coronary syndromes (ACS; unstable angina or myocardial infarction, n=450,329) at

168 In the MIRACL trial, 3,086 patients with unstable angina or non-Q-wave myocardial infarction were

169 tive PCI for stable angina or urgent PCI for unstable angina or non-ST segment elevation myocardial i

170 Unstable angina or non-ST-elevation myocardial infarctio

171 ND PATIENTS: Patients with medically managed unstable angina or non-ST-segment elevation myocardial i

172 nts with multivessel disease presenting with unstable angina or non-ST-segment elevation myocardial i

173 -eluting stent implantation in patients with unstable angina or non-ST-segment elevation myocardial i

174 High-risk patients with unstable angina or non-ST-segment-elevation myocardial i

175 baseline and in patients with stable angina, unstable angina, or a history of myocardial infarction.

176 , myocardial infarction, hospitalization for unstable angina, or any coronary revascularization).

177 adverse events of congestive heart failure, unstable angina, or arrhythmia--with the use of pooled d

178 atal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.

179 l infarction, stroke, hospital admission for unstable angina, or coronary revascularisation.

180 dial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key sec

181 l infarction, stroke, hospital admission for unstable angina, or coronary revascularization.

182 dial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

183 dial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

184 erial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).

185 erial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.

186 and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure

187 , myocardial infarction, hospitalization for unstable angina, or major procedural complication.

188 r adverse cardiac events (cardiac death, MI, unstable angina, or progressive angina) at latest follow

189 onstituting non-ST-segment elevation AMI and unstable angina, or stable angina pectoris (SAP).

190 CE) defined by death, myocardial infarction, unstable angina, or urgent coronary revascularization.

191 )-myocardial infarction, hospitalization for unstable angina, or urgent/emergency coronary revascular

192 olecule 1 (P<0.001), and previous history of unstable angina (P=0.01) were independent predictors of

193 -term mortality than patients diagnosed with unstable angina (P=0.05).

194 ts from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

195 ears in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

196 We linked Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

197 ta from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

198 ta from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

199 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

200 lled in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

201 ting in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

202 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

203 08 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

204 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

205 lled in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

206 on, and the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

207 he CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

208 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

209 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

210 00 CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with

211 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

212 he CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with

213 ting in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

214 E Registry (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With

215 In biomarker-negative stable and unstable angina patients undergoing elective PCI, the tr

216 The crude all-cause 1-year mortality for unstable angina patients with H-FABP <5.8 microg/l was 2

217 Patients with MI and unstable angina pectoris had higher VEGF levels compared

218 ents with acute coronary syndrome (82 MI, 44 unstable angina pectoris).

219 ligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial

220 ents presenting with stable angina pectoris, unstable angina pectoris,and ST-segment elevation myocar

221 ed in patients with myocardial infarction or unstable angina pectoris.

222 oronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coro

223 hypertension; diabetes mellitus; nonsmokers; unstable angina; previous coronary artery bypass graftin

224 ts (acute myocardial infarction, arrhythmia, unstable angina, pulmonary embolism) and little or no as

225 , neurological disease, active endocarditis, unstable angina, recent myocardial infarction, and pulmo

226 CHD events including coronary insufficiency/unstable angina, recognized myocardial infarction, coron

227 In patients in whom unstable angina remains a concern or there is a desire t

228 , death, reinfarction, rehospitalization for unstable angina, repeat coronary revascularization (targ

229 ion, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospital admission.

230 rate of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization at 4 years.

231 and either an acute myocardial infarction or unstable angina requiring hospitalization within the pre

232 l myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization) in multivaria

233 ction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower wit

234 fatal stroke, coronary revascularization, or unstable angina requiring hospitalization.

235 l myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization.

236 ction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.

237 l myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization.

238 site of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization; the secondary

239 cular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re

240 ath due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revasculari

241 ll causes, myocardial infarction, documented unstable angina requiring rehospitalization, revasculari

242 any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revasculari

243 ary end point (death, myocardial infarction, unstable angina requiring rehospitalization, stroke, or

244 ch additionally included hospitalisation for unstable angina requiring unplanned revascularisation) a

245 rction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or c

246 osites of death, myocardial infarction (MI), unstable angina, revascularization >30 days, and stroke

247 Secondary outcomes (unstable angina, revascularization procedures) were abst

248 end point was death, myocardial infarction, unstable angina, revascularization, or stroke (mean foll

249 The third Randomized Intervention Trial of unstable Angina (RITA-3) evaluated early IS (n = 895) ve

250 ere was a reduction in rehospitalization for unstable angina (RR = 0.69, 95% CI 0.65 to 0.74, p < 0.0

251 A significant reduction in unstable angina (RR, 0.64 [95% CI, 0.45-0.92]) and incre

252 art failure (CHF) within 4 weeks before CEA; unstable angina; steroid-dependent chronic obstructive p

253 h, acute MI, new congestive heart failure or unstable angina, stroke, and significant ventricular arr

254 dial infarction, coronary revascularization, unstable angina, stroke, or congestive heart failure.

255 , but before unblinding, hospitalization for unstable angina that led to urgent revascularization was

256 subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combinat

257 ugh early invasive therapy reduces recurrent unstable angina, the magnitude of benefit on other impor

258 The diagnosis in 2 women was upgraded from unstable angina to AMI, and the diagnosis in 1 man was d

259 155 to 271 mg/dl 3 to 36 months after MI or unstable angina to placebo or pravastatin 40 mg per day.

260 ere bleeding according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and T

261 l alone versus aspirin alone, Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) in fa

262 The incidence of Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) major

263 Patients (n=5059) from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) rando

264 r ACS was demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial

265 lopidogrel and placebo (CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clo

266 In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CU

267 non ST-elevation myocardial infarction, and unstable angina) to compare rates of cardiac procedures

268 entional Treatment Strategy in Patients with Unstable Angina) trials for a collaborative meta-analysi

269 routine invasive approach for patients with unstable angina (UA) and non-ST-segment elevation myocar

270 ne early use of clopidogrel in patients with unstable angina (UA) and non-ST-segment elevation myocar

271 for unplanned coronary revascularization and unstable angina (UA) are common.

272 creased CHD death/myocardial infarction (MI)/unstable angina (UA) event rate in carriers of the GP1BA

273 by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE)

274 real-world, medically managed patients with unstable angina (UA) or non-ST-segment elevation myocard

275 The secondary endpoint was MACE + unstable angina (UA) receiving early (<=24 h) revascular

276 ent elevation myocardial infarction (NSTEMI)/unstable angina (UA) who were managed medically without

277 oronary intervention for stable angina (SA), unstable angina (UA), or acute myocardial infarction (AM

278 myocardial infarction (STEMI), non-STEMI, or unstable angina (UA).

279 re 2 trials of an early invasive strategy in unstable angina (UA)/non-ST-elevation myocardial infarct

280 ) bleeding among patients with elective PCI, unstable angina (UA)/non-ST-segment elevation myocardial

281 nder and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial

282 ] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronar

283 g angiography within 2 months of their index unstable angina versus 0.097 (CI, 0.090 to 0.105) for th

284 n-ST-segment-elevation myocardial infarction/unstable angina versus elective) and PCI volume.

285 ard ratio, 4.06; 95% CI, 1.84-8.94; P<0.001; unstable angina versus non-ACS: adjusted hazard ratio, 1

286 iovascular event plus hospital admission for unstable angina was greater than 1.3, a dedicated study

287 ion, ischemic stroke, or hospitalization for unstable angina) was examined according to American Coll

288 (n=8) specimens from patients with stable or unstable angina were classified as complicated or uncomp

289 atal events; and 1.21 (1.04-1.41) if TIA and unstable angina were further excluded.

290 ndomized trial, 2008 patients with stable or unstable angina were randomly assigned in a 2:1 ratio to

291 d recurrent ischemic events (recurrent MI or unstable angina) were identified through Olmsted County,

292 MRS was primarily due to hospitalization for unstable angina, which is associated with repeat cathete

293 cardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hosp

294 ed with a lower risk of nonprocedural MI and unstable angina with greater freedom from angina at the

295 -segment elevation myocardial infarction, or unstable angina with high-risk features) or nonacute ind

296 cardiovascular death, myocardial infarction, unstable angina with revascularization, and heart failur

297 spitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes occurred between F

298 tion myocardial infarction within 7 days, or unstable angina within 48 h of randomization.

299 infarction or who had been hospitalized for unstable angina within the previous 180 days to receive

300 ninvasive stress results (n = 1906; 57%) and unstable angina without high-risk features (n = 902; 27%